Overview
Teiko.bio develops immune profiling tools for biopharma and personalized cancer therapy. It analyzes interactions between immune cells and tumor cells to generate actionable data that helps drug development and patient selection; its core offering is the TokuProfile panel with 35+ immune markers that creates an immune fingerprint for each patient, enabling predictive marker identification and tracking treatment impact. This differentiates Teiko.bio by providing end-to-end, tailored immune profiling and data analysis for drug development, target validation, and patient stratification, rather than generic assays. The goal is to help biopharma companies develop more effective therapies and improve clinical outcomes by supplying precise immune data and insights throughout the development process.
Work here?Claim your company
Simplify's take
What believers are saying
- Teiko launched Assay Qualification Reports on October 14, 2026, strengthening enterprise adoption.
- SITC 2026 presentations on November 3 expand visibility for stabilized samples and AI panel design.
- Stingray Therapeutics and Obsidian Therapeutics broaden proof that biopharma pays for Teiko profiling.
What critics are saying
- Teiko still relies on a 2021 disclosed $11.6 million Series A runway.
- CellCarta and other vendors can copy dashboard features faster than Teiko can defend them.
- If one major oncology sponsor leaves after a failed readout, revenue concentration turns existential.
What makes Teiko unique
- Teiko combines CLIA immune profiling, stabilized whole blood, and dashboard analytics.
- Its 2026 assays quantify antigen density, phosphoproteins, and functional subsets in one workflow.
- University of Utah Health invested and co-develops AML tests, deepening clinical credibility.
Help us improve and share your feedback! Did you find this helpful?